Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Terazosin hydrochloride dihydrate (Heitrin dihydrate) 是一种竞争性和口服活性的 α1-肾上腺素受体(α1-adrenoceptor) 拮抗剂,是一种喹唑啉衍生物,通过舒张血管和打开膀胱的方式起作用。它可用于研究良性前列腺增生 (BPH) 和高血压。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 272 | 现货 | ||
50 mg | ¥ 375 | 现货 | ||
100 mg | ¥ 574 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 410 | 现货 |
产品描述 | Terazosin hydrochloride dihydrate (Heitrin dihydrate) is a selective α1-adrenoceptor antagonist, used for treatment of symptoms of an enlarged prostate (BPH). |
体外活性 | Terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner in prostate cancer cells. Terazosin suppresses prostate growth potentially via α 1-adrenoceptor-independent actions gains further support from another study documenting that Doxazosin inhibits proliferation of human vascular smooth muscle cells independently of an antagonistic effect on α1-adrenoceptor. [1] Terazosin blocks HERG currents in Xenopus oocytes with IC50 of 113.2 mM, while Terazosin blocks HERG channel inhibition in human HEK 293 cells with IC50 of 17.7 mM. [2] Terazosin or genistein treatment inhibits the growth of DU-145 cells in a dose-dependent manner, whereas has no effect on normal prostate epithelial cells. Terazosin results in the genistein-induced arrest of DU-145 cells in G2/M phase being overridden and an increase in apoptotic cells, as evidenced by procaspase-3 activation and PARP cleavage. [3] Terazosin induces cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 mM. [4] |
体内活性 | Terazosin significantly inhibits vascular endothelial growth factor induced angiogenesis in nude mice with an IC50 of 7.9 mM, showing that it has a more potent anti-angiogenic than cytotoxic effect. Terazosin also effectively inhibits vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 mM, respectively). [4] |
别名 | Flotrin dihydrate, Terazosin HCl Dihydrate, Dysalfa dihydrate, Heitrin dihydrate, 盐酸特拉唑嗪(二水合物) |
分子量 | 459.92 |
分子式 | C19H25N5O4·HCl·2H2O |
CAS No. | 70024-40-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 25 mg/mL (54.4 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
Ethanol: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.1743 mL | 10.8715 mL | 21.7429 mL | 54.3573 mL |
5 mM | 0.4349 mL | 2.1743 mL | 4.3486 mL | 10.8715 mL | |
10 mM | 0.2174 mL | 1.0871 mL | 2.1743 mL | 5.4357 mL | |
20 mM | 0.1087 mL | 0.5436 mL | 1.0871 mL | 2.7179 mL | |
50 mM | 0.0435 mL | 0.2174 mL | 0.4349 mL | 1.0871 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Terazosin hydrochloride dihydrate 70024-40-7 GPCR/G Protein Neuroscience Adrenergic Receptor Inhibitor bladder Beta Receptor inhibit Flotrin dihydrate Flotrin Dihydrate Terazosin HCl pressure α1-adrenoceptor Heitrin Dysalfa Dihydrate Terazosin Hydrochloride Terazosin HCl Dihydrate quinazoline blood Heitrin Dihydrate Dysalfa dihydrate benign Heitrin dihydrate prostatic Dysalfa Flotrin hyperplasia Terazosin hydrochloride Dihydrate high 盐酸特拉唑嗪(二水合物) inhibitor